Blueprint Medicines Secures $25,000,000 Series B Round

  • Feed Type
  • Date
    1/7/2014
  • Company Name
    Blueprint Medicines
  • Mailing Address
    215 First Street Cambridge, MA 02142
  • Company Description
    Blueprint Medicines is driving the development of personalized, highly-selective cancer therapies that harness the growing understanding of the molecular blueprint of cancer.
  • Website
    http://www.blueprintmedicines.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $25,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Blueprint’s lead programs include the first known selective inhibitors of the KIT D816V mutation, which is the genomic driver of the underserved systemic mastocystosis patient population, as well as a key genomically defined subset of patients with gastrointestinal stromal tumors (GIST). The Company’s pipeline also includes the first known isoform-selective FGFR4 inhibitors for patients with hepatocellular carcinoma with FGF19 amplification, the first clear genomic driver in liver cancer, and other tumors. Blueprint expects to initiate clinical trials for these programs in 2015.
  • M&A Terms
  • Venture Investor
    Nextech Invest
  • Venture Investor
    Third Rock Ventures
  • Venture Investor
    Fidelity BioSciences
  • Venture Investor
    Casdin Capital
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.